Synthetic glioblastoma mutated tumor-specific peptides vaccine therapy APVAC2

{
  "id": "MLC-T-ONC-016939",
  "term": "Synthetic glioblastoma mutated tumor-specific peptides vaccine therapy APVAC2",
  "field": "Oncology and biomedicine",
  "definition": "A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient’s own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/synthetic-glioblastoma-mutated-tumor-specific-peptides-vaccine-therapy-apvac2/"
}